NEW YORK (CNNMoney) -- Johnson & Johnson's McNeil division announced a recall of certain Tylenol brand products Friday after a review of cleaning procedures at a plant in Fort Washington, Pa.
Conducted in consultation with the Food and Drug Administration, the recall covers certain lots of Tylenol 8 Hour, Tylenol Arthritis Pain, and Tylenol upper respiratory products, as well as some Benadryl, Sudafed PE and Sinutab products.
The latest recall comes after a review of McNeil's Fort Washington factory, which has been closed due to its production problems since early May, found equipment cleaning procedures were insufficient or that cleaning was not adequately documented.
It is "very unlikely" that product quality was affected, and no action is required by consumers or healthcare providers. Consumers can continue to use the product, Johnson & Johnson said in a statement.
The recall affects more than 45 million products, a spokeswoman for the company said.
The drugs were produced by the company's troubled McNeil division, which has been dogged for over a year by a series of recalls and critical oversight actions by the Food and Drug Administration and federal lawmakers.
On Wednesday, Oregon became the first state to file a lawsuit against J&J over a "phantom" recall of Motrin drugs.
The suit alleges that the company's McNeil division sold faulty Motrin drugs in gas stations and convenience stores nationwide in 2008, and then secretly removed the products from store shelves.
On Friday, CNNMoney learned that a multi-state investigation into Johnson & Johnson's handling of drug recalls is under way.
Land O'Lakes CEO Beth Ford charts her career path, from her first job to becoming the first openly gay CEO at a Fortune 500 company in an interview with CNN's Boss Files. More
Honda and General Motors are creating a new generation of fully autonomous vehicles. More
In 1998, Ntsiki Biyela won a scholarship to study wine making. Now she's about to launch her own brand. More
Whether you hedge inflation or look for a return that outpaces inflation, here's how to prepare. More